dEEGtal Insight secures CHF 1M to revolutionize epilepsy diagnosis
13.12.2024
Swiss startup dEEGtal Insight SA has raised CHF 1 million in seed funding to advance its innovative technology aimed at enhancing the accuracy of epilepsy diagnosis. The company's solution addresses current challenges by improving detection precision and providing clinicians with better guidance in identifying epileptic conditions.
 CTO Stefano Gallotto and CEO Eric Ménétré
|
 |
Each year, around 10 million people worldwide experience a possible first epileptic seizure, but up to 80% of initial EEG readings appear normal. This delays diagnoses and increases the risk of relapse to 70% in untreated patients, significantly impacting their quality of life, including work and driving restrictions.
dEEGtal leverages AI models trained on extensive EEG datasets to provide a risk score even when standard visual signs of epilepsy are absent. Its user-friendly platform includes automated medical reporting and integration into clinical workflows.
The startup raised CHF 1 million in seed funding, with CHF 750,000 from the Wyss Center, to refine its AI models, validate them clinically, and prepare for regulatory approval. dEEGtal aims to secure FDA clearance for the U.S. market and CE marking for Europe and Switzerland.
As the global epilepsy diagnostics market grows from CHF 3.3 billion in 2024 to over CHF 10 billion by 2032, dEEGtal's innovative approach positions it to capture a significant share by enhancing diagnostic accuracy and addressing related conditions like syncope and stroke.
dEEGtal won Venture Kick in 2024.
dEEGtal leverages AI models trained on extensive EEG datasets to provide a risk score even when standard visual signs of epilepsy are absent. Its user-friendly platform includes automated medical reporting and integration into clinical workflows.
The startup raised CHF 1 million in seed funding, with CHF 750,000 from the Wyss Center, to refine its AI models, validate them clinically, and prepare for regulatory approval. dEEGtal aims to secure FDA clearance for the U.S. market and CE marking for Europe and Switzerland.
As the global epilepsy diagnostics market grows from CHF 3.3 billion in 2024 to over CHF 10 billion by 2032, dEEGtal's innovative approach positions it to capture a significant share by enhancing diagnostic accuracy and addressing related conditions like syncope and stroke.
dEEGtal won Venture Kick in 2024.